BioSpace News Archive

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences.

INVO Bioscience, Inc. (NASDAQ: INVO), announced today that Dr. Inger Britt Carlsson will be presenting at the Association for Fertility and Reproductive Health (AFRH) virtual conference this year on September 23rd and 24th on the topic of INVOcell® as an efficient, patient-centric and affordable fertility solution for the continent of Africa.

Avidity Science, a worldwide leader in life science research tools, today announces it has sold its subsidiaries of Lab Products, LLC and Harford Systems, LLC to Gen Cap America, Inc. (“Gen Cap”), a private equity firm focused on lower middle market buyouts.

The Public Health Agency of Canada continues to monitor COVID-19 epidemiological indicators to quickly detect, understand and communicate emerging issues of concern.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 132,000 shares of the company’s common stock to four new employees.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has submitted for a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that management will present at the following investor conferences during the month of September 2021.

Jaguar Health, Inc. announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock, at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021.